Processa regains Nasdaq minimum bid price compliance; delisting risk resolved

Processa Pharmaceuticals, Inc.

Received written notice from Nasdaq on Feb 6, 2024 confirming compliance with Listing Rule 5550(a)(2).
Achieved minimum $1.00 closing bid price for 10 consecutive business days ending Feb 2, 2024.
Matter is now closed; no further deficiency or delisting action pending.
Stock ticker PCSA; compliance removal removes immediate delisting overhang.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.